98%
921
2 minutes
20
Background: The impact of age on outcomes after revascularization for chronic limb-threatening ischemia has not been studied in a prospective trial.
Methods: A total of 1780 patients were grouped into age quartiles (≤55 years, 55< age ≤65 years, 65< age ≤75 years, and >75 years) and by type of revascularization (open bypass or endovascular). The primary outcome was major adverse limb events (MALE) or death, and the secondary outcomes were above-ankle amputation, reintervention, and major adverse cardiovascular events.
Results: Death and major adverse cardiovascular events were significantly higher in the oldest quartile (>75 years), whereas MALE and above-ankle amputation were highest in the youngest cohort (≤55 years). Younger patients (≤55 years) had the lowest adjusted risk of MALE or all-cause death with open bypass compared with endovascular revascularization. There was no difference in MALE or all-cause death by treatment strategy in patients >75 years of age.
Conclusions: Older age was associated with the highest risks of death and major adverse cardiovascular events and the lowest risks of MALE and above-ankle amputation among patients enrolled in BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Chronic Limb-Threatening Ischemia). Age also had a differential impact by revascularization strategy: youngest patients had the lowest risk of MALE and all-cause death with bypass surgery compared with endovascular revascularization, while there was no difference among those >75 years. These data should be used to facilitate shared decision-making in patients with chronic limb-threatening ischemia.
Registration: URL: https://biolincc.nhlbi.nih.gov/studies/best_cli/; Unique identifier: HLB02932424a.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173781 | PMC |
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.124.014833 | DOI Listing |
Ann Vasc Surg
September 2025
Department of Cardiovascular Surgery, Hiroshima University Hospital, 1-2-3Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Background: Polypharmacy or hyperpolypharmacy in elderly patients has been associated with poor prognosis and cardiovascular events due to side effects and drug interactions. Patients with chronic limb-threating ischemia (CLTI) have many comorbidities that may need multiple drugs. The purpose of this study is to evaluate clinical outcomes in these patients with or without hyperpolypharmacy.
View Article and Find Full Text PDFJ Vasc Surg
September 2025
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale School of Medicine, New Haven, CT.
Introduction: Although smoking cessation has been shown to improve outcomes after lower extremity revascularization (LER), the impact of cessation duration has not been well defined. This study investigates the impact of two cessation durations on LER outcomes in patients with chronic limb-threatening ischemia (CLTI).
Methods: The Peripheral Vascular Intervention, Infrainguinal Bypass, and Suprainguinal Bypass modules of the Vascular Quality Initiative (VQI) were utilized to identify patients whose first recorded LER occurred between 2016-2024 for CLTI.
Vasc Endovascular Surg
September 2025
Division of Vascular Surgery, NorthWest Hospital Group, Amsterdam, The Netherlands.
ObjectiveRestenosis limits the benefit of below-the-knee (BTK) endovascular therapy (EVT). Restenosis may be attributable to limited information from digital subtraction angiography. A promising alternative is intravascular ultrasound (IVUS).
View Article and Find Full Text PDFJ Med Cases
August 2025
Department of Surgery, Arrowhead Regional Medical Center, Colton, CA 92324, USA.
Our study aims to estimate the long-term cost of procedurally successful transcatheter arterialization of the deep veins (TADV) coupled with adjunct therapy. Patients with no conventional endovascular/open options were considered for TADV. TADV index procedure cost, cost of subsequent procedures and wound care/adjuncts were collected.
View Article and Find Full Text PDFLancet
August 2025
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Background: Drug-coated devices are frequently used in coronary and peripheral interventions, but their effect on amputation risk in peripheral artery disease is unclear. We assessed whether drug-coated devices affect the rate of above-ankle amputation in patients with chronic limb-threatening ischaemia undergoing infrainguinal endovascular revascularisation.
Methods: The Swedish Drug-Elution Trial in Peripheral Arterial Disease 1 (SWEDEPAD 1) was a pragmatic, nationwide, multicentre, participant-masked, registry-based, randomised controlled trial at 22 Swedish centres.